Annotation Detail

Information
Associated Genes
EGFR
Associated Variants
EGFR EXON 19 DELETION ( ENST00000275493.7 )
EGFR EXON 19 DELETION ( ENST00000275493.7 )
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
Non-small cell cancer patients from two studies [The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)] with exon 19 deletion and L858R EGFR (Exon 21) mutations were pooled to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. Median progression-free survival and median survival were better following dacomitinib treatment (14.6 and 26.6 months, N=53) than erlotinib (9.6 and 23.2, P = 0.146 and P = 0.265, N=48). In exon 19 mutated patients (N=32 and 36) PFS was better for dacomitinib treated patients (HR of 0.585 [95% CI 0.335–1.024], two-sided log-rank, P = 0.058) but did not reach significance.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/4859
Gene URL
https://civic.genome.wustl.edu/links/genes/19
Variant URL
https://civic.genome.wustl.edu/links/variants/133
Rating
3
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Dacomitinib,Erlotinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
26768165
Drugs
Drug NameSensitivitySupported
DacomitinibSensitivitytrue
ErlotinibSensitivitytrue